Press Release

Cyxone's presentation at Aktiedagen 27 January now published

January 28, 2021 09:12 (CET)

Cyxone’s CEO Tara Heitner presented the company at Aktiespararnas Aktiedagen on 27 January 2021. Click here to see the video (


Tara Heitner, CEO
Tel: +46 70 781 88 08
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, For more information, please visit

Open Press release